Overview

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

Status:
Recruiting
Trial end date:
2022-10-30
Target enrollment:
0
Participant gender:
All
Summary
This phase I trial will assess primarily the safety and secondarily the anti-inflammatory and anti-neovascular effect of Episcleral Celecoxib in patients suffering from macular edema and other inflammatory disorders of the retina, choroid and vitreous.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Targeted Therapy Technologies, LLC
Treatments:
Celecoxib
Criteria
Inclusion Criteria:

- Age >= 18 years;

- Visual acuity letter score in study eye < 70 and ≥ 25 letters (approximate Snellen
equivalent 20/32 to 20/320);

- Ophthalmoscopic evidence of center-involved macular edema, within the central subfield
(CSF); • Inflammatory disorders of the sclera, choroid, retina or vitreous

Exclusion Criteria:

- Inability to understand informed consent, cooperate with testing or return to follow
up visits;

- Pregnant or lactating women;

- Co-existent ocular disorder of the cornea, lens or media that will interfere with
assessment of safety or efficacy.